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Background: This study was conducted to assess the risk of surgical treatment and to evaluate surgical resection
in patients with pulmonary aspergilloma.
Method:We reviewed 240 patients with pulmonary aspergilloma who were diagnosed between 1990 and 2006.
Of these, 135 patients underwent surgical procedure (group A) and 105 patients were managed with conservative
treatment (group B).
Result: Forty complications (29.6%) and 6 operative mortalities (4.4%) developed in group A. During the fol-
low-up period, there were 5 recurrences (3.9%) after surgical procedure. The overall 10-year survival rates of
group A and group Bwere 84.8% and 56.7% (P<.001). In multivariate analysis, age, sex, and surgical treatment
were favorable prognostic factors. Symptoms of hemoptysis and blood-tinged sputum were not significant prog-
nostic factor even in univariate analysis.
Conclusion: Our results indicate that (1) early morbidity and mortality rates of surgical treatment for pulmonary
aspergilloma are acceptable, and (2) surgical treatment is helpful not only to reduce symptoms but also to prolong
the survival of patients with pulmonary aspergilloma. Although more studies are needed, our data support the
conclusion that surgical resection should be considered for all patients with pulmonary aspergilloma who have
acceptable pulmonary reserve.Pulmonary aspergilloma generally forms from saprophytic
colonization of preexisting pulmonary cavities of Aspergil-
lus fulmigatus, the most common saprophytic species of
Aspergillus in human disease, producing a fungus ball or
a mycetoma.1,2 Massive or repetitive hemoptysis from the
intrapulmonary lesion is life-threatening,3 and antifungal
agents do not completely eradicate the fungus ball estab-
lished in the pulmonary cavities.4 Surgical resection of the
localized pulmonary lesion contributes not only to reducing
symptoms but also to the likelihood of a permanent cure for
aspergilloma.3,5,6 Although recent advances in thoracic sur-
gery have indicated favorable acute and long-term out-
comes7-10 compared with early high morbidity and high
mortality rates5,11-14 with the management of pulmonary as-
pergilloma, there is at present no consensus about the role
of surgical resection in the treatment of pulmonary asper-
gilloma.
This study focuses on the clinical outcome of patients with
pulmonary aspergilloma. Our primary objectives were to as-
sess the risk of surgical treatment and to evaluate the surgical
resection in the treatment of pulmonary aspergilloma.
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Patients and Methods
We reviewed the records of patients with pulmonary aspergilloma who
were diagnosed at our institution between January 1990 and December
2006. During this period, 240 patients were diagnosed with pulmonary
aspergilloma. Of these, 135 patients underwent surgical procedure
(group A). The patients were evaluated for clinical variables and were
compared with 105 patients who were managed with nonsurgical treat-
ment (group B) during the same period. Patients with invasive aspergillo-
sis or allergic bronchopulmonary aspergillosis were excluded from this
study. Diagnosis of aspergilloma was made on the basis of clinical symp-
toms and radiologic findings, such as tomography or computed tomo-
graphic scans. Fiberoscopic bronchoscopy was performed to identify the
bleeding focus. Percutaneous needle aspiration biopsy was performed
when malignancy was suspected. We selected patients for surgery if
they exhibited symptoms or presented with undetermined mass lesions.
We routinely prescribed an oral antifungal agent (itraconazole) to be
administered for 3 months following surgical resection of pulmonary
aspergilloma. After the late 1990s, we preferred surgical procedure for
symptomatic and asymptomatic pulmonary aspergilloma because favor-
able surgical series7-10 had been reported. In cases with poor pulmonary
reserve or a high risk of undergoing a thoracotomy, we recommended con-
servative treatment such as bed rest, bronchial artery embolization, and an-
titussive medication. The types of aspergilloma were classified
retrospectively according to the classification of Belcher and Plummer5:
aspergilloma was considered the simple type when it developed in isolated
thin-walled cysts lined by ciliated epithelium and the surrounding lung
was normal; it was considered the complex type when the lesion devel-
oped in cavities formed by gross disease in the surrounding lung tissue.
Follow-up data were obtained from the outpatient clinic chart reviews or
by telephone calls to patients or families.
The Institutional Review Board of Yonsei University College of Medi-
cine approved this retrospective study. The need for a subsequent individual
consent of patients whose records were evaluated was waived because the
individuals were not identified within the study.gery c October 2009
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The association between variables was analyzed by either the chi-square
or t test. The operative mortality was defined as in-hospital mortality or mor-
tality before postoperative day 30. Deaths owing to all causes including op-
erative mortality were included in the survival statistics. The survival was
calculated from the date of operation in group A and 12 months after diag-
nosis (one-half the interval of majority [90%] in group A had their operation
after diagnosis) in group B. Patients (n¼ 13) who died or who had less than
12 months’ follow-up after diagnosis in group B were dropped in the sur-
vival analysis. All patients were followed until either the date of death or
the last follow-up (Aug 31, 2007).
The covariates in the univariate model included age, sex, pulmonary
function, aspergilloma type, symptom, underlying lung disease, and treat-
ment. The differences in survival among groups were examined using
a log-rank test, and multivariate analyses were performed by means of the
Cox proportional hazard model in variables that had P values less than
.05 by univariate analyses. In a subgroup analysis, a propensity-matched
analysis was used to adjust for selection bias between group A and group
B. The propensity score was calculated for each patient on the basis of a lo-
gistic regression analysis of the predicted probability. Age, sex, aspergil-
loma type, and pulmonary function test were used as candidate variables
in this propensity model. The significant predictors of treatment type were
used to match each patient in the group A to a patient in the group B with
the same set of predictors. A total of 114 (57 in group A and 57 in group
B) of 240 patients were matched. The data were analyzed using SPSS for
Windows (Statistical Package for Social Science, SPSS Inc. Chicago, Ill).
RESULTS
Demographic Characteristics
The patients included 136men and 104 women with a me-
dian age of 51 years (range, 12–80). Clinical characteristics
of patients in group A and B are compared in Table 1.
Patients in group A were younger and had better pulmonary
function than patients in group B. There were no significant
differences in sex, underlying lung disease, and type of as-
pergilloma. Tuberculosis was the most common underlying
lung disease. The main signs and symptoms were hemopty-
sis and blood-tinged sputum, and the right upper lobe and
left upper lobe were the main locations. Median size of re-
sected aspergilloma was 4.0 cm (range, 1.0–10.0).
Treatment of Pulmonary Aspergilloma
Bronchial artery embolization was attempted in 35 pa-
tients due to repeated or massive hemoptysis. Of these, 19
patients underwent surgical procedure and 16 patients
were observed with medical treatment. Ultimately, 135 pa-
tients underwent surgical procedure (group A). The surgical
procedures were lobectomy in 85 patients (60.8%), pneu-
monectomy in 21 patients (15.6%), segmentectomy in 19
patients (14.1%), wedge resections in 12 patients (8.9%),
and cavernostomy with thoracoplasty in 1 patient (0.7%)
who had a previous history of lobectomy. Surgical indication
was repeated hemoptysis in 73 patients (54.0%), massive
hemoptysis in 12 patients (8.9%), indeterminate nodule in
36 patients (26.6%), and uncontrolled infection in 14 pa-
tients (10.4%). Uncontrolled infection included lung
abscess (n ¼ 3), empyema (n ¼ 3), destroyed lung with
recurrent infection (n ¼ 5), infected bulla (n ¼ 1), andThe Journal of Thoracic and Ctuberculosis with persistent positive sputum acid-fast bacilli
(n¼ 2). The median time interval between the diagnosis and
surgical procedure was 0.7 months (range, 0–85.6 months).
The reasons for nonsurgical treatment of 105 patients were
bilateral location in 17 patients (16.2%), low pulmonary re-
serve in 23 patients (21.9%), refusal by the patient or family
in 13 patients (12.4%), medical observation in 20 patients
(19.0%), no positive symptoms (hemoptysis or blood-tinged
sputum) present in 24 patients (22.9%), and comorbidity in
8 patients (7.6%) (3 with cancer, 2 with old age, 2 with liver
disease, and 1 with dilated cardiomyopathy).
Surgical Outcome
Forty patients of the 135 patients in group A had compli-
cations (29.6%): prolonged air leakage>7 days in 13 pa-
tients, incomplete reexpansion in 7 patients, postoperative
bleeding in 7 patients, bronchopleural fistulae in 4 patients,
TABLE 1. Clinical characteristics of the patients
Variables
Group A
(n ¼ 135)
Group B
(n ¼ 105) P value
Age, median (range) 48 (12–74) 54 (23–80) <.001
Sex, n (%) .237
Male 72 (53.3%) 64 (61.0%)
Female 63 (46.7%) 41 (39.0%)
Underline lung disease, n (%) .339
Tuberculosis 79 (58.5%) 73 (69.5%)
Bronchiectasis 22 (16.3%) 9 (8.6%)
Lung abscess 7 (5.2%) 3 (2.9%)
Empyema 4 (3.0%) 1 (1.0%)
Carcinoma 2 (1.5%) 1 (1.0%)
Emphysema 3 (2.2%) 1 (1.0%)
None 18 (13.3%) 17 (16.2%)
Type of aspergilloma, n (%) .523
Simple 33 (24.4%) 22 (21.0%)
Complex 102 (75.6%) 83 (79.0%)
Pulmonary function* <.001
FEV1 (L) 2.47  0.9 1.72  0.8
FEV1 (%) 83.1  23.0 64.9  27.9
FVC (L) 3.04  0.9 2.30  0.9
FVC (%) 83.8  19.9 66.4  23.9
Symptoms and sign, n (%) .009
Hemoptysis 83 (61.5%) 47 (44.8%)
Blood-tinged sputum 21 (15.6%) 12 (11.4%)
Cough and sputum 11 (8.1%) 15 (14.3%)
Chest pain 4 (3.0%) 3 (2.9%)
Dyspnea 3 (2.2%) 12 (11.4%)
None 13 (9.6) 16 (15.2%)
Location, n (%) .068
Right upper lobe 53 (39.3%) 44 (41.9%)
Right middle lobe 1 (0.7%) —
Right lower lobe 21 (15.6%) 8 (7.6%)
Left upper lobe 43 (31.9%) 33 (31.4%)
Left lower lobe 12 (8.9%) 7 (6.7%)
Multiple locations 5 (3.7%) 13 (12.4%)
FEV1, Forced expiratory volume for 1 second; FVC, forced vital capacity. *Pulmonary
function tests were available in 182 patients.ardiovascular Surgery c Volume 138, Number 4 821
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No. Age/Sex FEV1 (%) Aspergilloma type Procedure Complication Procedure for complication Cause of death
1 46/male 2.30 (71.0) Complex Lobectomy BPF and empyema Completion pneumonectomy Pneumonia
2 66/male 0.93 (41.2) Complex Pneumonectomy Bleeding Bleeding control Pneumonia
3 53/female — Complex Pneumonectomy — — Pneumonia
4 70/male 0.88 (35.0) Complex Lobectomy Bleeding Bleeding control Pneumonia
5 68/male 1.20 (49.9) Complex Lobectomy BPF and empyema Completion pneumonectomy Pneumonia
6 53/male 3.50 (100.0) Complex Pneumonectomy — — Cardiovascular
FEV1, Forced expiratory volume for 1 second; BPF, bronchopleural fistula.wound infection in 3 patients, empyema in 3 patients, and
pneumonia in 3 patients. There were 6 cases (4.4%) of op-
erative mortality that all occurred in the complex aspergil-
loma. Three of 6 operative mortalities occurred after
pneumonectomy, and 2 of 6 operative mortalities occurred
after the completion of pneumonectomy due to complica-
tions. Causes of death were postoperative pneumonia (n ¼
5) and cardiovascular event (n ¼ 1) (Table 2). During the
follow-up period, we had 5 recurrences after the surgical
procedure, giving a recurrence rate of 3.9% (10-year recur-
rence free survival was 74.8% in group A). The recurrences
developed 47, 75, 79, 101, 147 months after surgical proce-
dure. One patient was treated by thoracoplasty and is alive
and symptom-free. The others were managed with conserva-
tive treatment because of poor respiratory reserve and are
still alive with intermittent hemoptysis or blood-tinged
sputum.
Causes of Death
The median follow-up time was 64.2 months (range, 0.4–
255.8 months). Eleven patients in group A and 41 patients in
group B died during the follow-up period. The causes of
death were identifiable in 9 patients for group A (respiratory
failure in 5, cancer related in 3, cardiovascular in 1) and in 36
patients for group B (hemoptysis related in 12, respiratory
failure in 11, cancer-related in 5, cardiovascular in 6, renal
failure in 1, hepatic failure in 1). We were not able to clarify
the cause of death for 2 patients in group A and for 5 patients
in group B.
Overall Survival
The overall 10-year survival rate of all patients was
74.0%. The overall 10-year survival rates of group A and
group B were 84.8% and 56.7% (P< .001), respectively
(Figure 1). A univariate analysis using the variables listed
in Table 3 showed that the following factors were signifi-
cantly associated with a good outcome: age  51, female
sex, good pulmonary reserve (forced expiratory volume
for 1 second> 79.6%), simple type of aspergilloma, and
surgical treatment. Hemoptysis and blood-tinged sputum
were not significant prognostic factors. Using multivariate
analysis, we found that the independent favorable prognostic
factors were age, sex, and surgical treatment (Table 4). In
a subgroup analysis with propensity score-matched group822 The Journal of Thoracic and Cardiovascular SurA (n ¼ 57) and group B (n ¼ 57), the overall 10-year sur-
vival rates of group A and group B were 78.1% and
52.3%, respectively (P ¼ .036).
DISCUSSION
This study indicated that early morbidity and mortality
rates after surgical treatment are acceptable. Surgical resec-
tion of pulmonary aspergilloma contributes not only to re-
ducing symptoms but also to the likelihood of a permanent
cure for aspergilloma. Long-term survival could be pre-
dicted with surgical treatment for patients with symptomatic
and asymptomatic pulmonary aspergilloma.
Aspergilloma is the most common and best-recognized
form of pulmonary involvement due to Aspergillus. Pulmo-
nary aspergilloma usually develops in a preexisting cavity in
FIGURE 1. Kaplan-Meier analysis of overall survival for group A and
group B.gery c October 2009
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aspergilloma, including tuberculosis, sarcoidosis, bronchi-
ectasis, bronchial cysts and bullae, ankylosing spondylitis,
neoplasm, and pulmonary infection15,16; of these, tuberculo-
sis is the most commonly associated condition.17 In a study
of 544 patients with pulmonary cavities secondary to tuber-
culosis, 11% had radiologic evidence of aspergilloma.18
Tuberculosis was also the most common underlying lung
disease in our series. The apical portion of the upper lobe
and the superior segment of the lower lobe were the most
common sites of disease in our study, which seems to reflect
an association with pulmonary tuberculosis.
Themost common symptom associated with aspergilloma
is hemoptysis.1 Approximately 70% of our patients had ei-
ther hemoptysis or blood-tinged sputum. Bleeding usually
occurs from bronchial blood vessels and may be due to local
invasion of blood vessels lining the cavity, endotoxins re-
leased from the fungus, or mechanical irritation of the ex-
posed vasculature inside the cavity by the rolling fungus
ball.19 Bleeding could originate from intercostal arteries as
well. Extension of the mycotic process with parenchymal
destruction at the periphery of the lung invading the adjacent
chest wall may lead to erosion of the intercostal arteries.20
Bleeding from such large arteries is unlikely to stop sponta-
TABLE 3. Prognostic factors in pulmonary aspergilloma by
univariate analysis
Variables
No. of
patients
10-year survival
rate (95%
confidence interval) P value
Age (y) <.001
51 118 92.8 (88.1–97.4)
>51 109 43.5 (34.2–52.8)
Sex <.001
Male 127 67.0 (58.8–75.2)
Female 100 83.6 (76.3–90.9)
FEV1 (%) .023
79.6 90 65.7 (55.9–75.5)
>79.6 92 83.8 (77.5–90.1)
Treatment <.001
Surgical 135 84.8 (79.7–89.9)
Nonsurgical 92 56.7 (48.2–65.2)
Type of aspergilloma .003
Simple 53 88.8 (80.3–97.3)
Complex 174 69.1 (62.2–75.9)
Symptoms* .074
Symptomatic 155 77.7 (71.2–84.3)
Asymptomatic 72 66.4 (55.5–77.3)
Underlying lung disease .157
Tuberculosis 149 70.6 (63.3–77.9)
Nontuberculosis 78 81.6 (73.0–90.2)
Location of aspergilloma .322
Upper lobe 164 71.0 (64.1–77.9)
Mid or lower lobe 63 81.1 (71.4–90.8)
FEV1, Forced expiratory volume for 1 second. *Symptoms: hemoptysis or blood-
tinged sputum.The Journal of Thoracic and Cneously and could be fatal. The mortality rate from hemop-
tysis related to aspergilloma ranges between 2% and
14%.3,21,22 Twelve patients (11.4%) of 105 from group B
died from a hemoptysis-related mechanism during the fol-
low-up period in our series. The majority of cases of pulmo-
nary aspergilloma remain stable and in 10% of cases, the
aspergilloma may decrease in size or resolve spontaneously
without treatment.23 Neither the size, the complexity of the
lesion, the presence of warning minor hemoptysis, nor the
type of underlying disease can predict those patients who
will progress to life-threatening hemoptysis.3 This threat
from pulmonary aspergilloma may be one of the primary
reasons for treatment.
There is no consensus on the treatment of aspergilloma.
Treatment is considered only when patients become symp-
tomatic, usually with hemoptysis. Inhaled, intracavitary,
and endobronchial instillations of antifungal agents have
been tried and reported in small numbers of patients, without
consistent success.3,24,25 The role of intravenously adminis-
tered amphotericin B is uncertain, and some small studies
failed to show a benefit.4 Oral itraconazole therapy has
been tried with variable results.26,27 Bronchial artery emboli-
zation is considered as a temporary measure in patients with
life-threatening hemoptysis, as hemoptysis usually recurs
due to the presence of massive collateral blood vessels.28
In the absence of effective medical treatment, surgery has
been regarded as the treatment of choice in operable patients
with symptoms, because it removes the source of bleeding.
Surgery usually offers 3 potential benefits: control of symp-
toms, prevention of recurrent hemoptysis, and possible pro-
longation of life. Patient selection for surgery depends on the
balance between the risk of disease and the risk of surgery.
Previous series reported mortality rates of up to 43% and
morbidity including hemorrhage, residual pleural space,
bronchopleural fistula, and empyema at rates of up to
60%.5,11-14 The fluctuating nature of the disease process
and the modest surgical results restricted surgery to patients
with significant symptoms. However, recent reports from the
early 2000s showed a dramatic reduction in surgical-related
mortality and morbidity.7-10 Reported mortality rates range
from 0 to 4%. Akbari and colleagues9 reported surgical
TABLE 4. Prognostic factors in pulmonary aspergilloma by
multivariate analysis
Variables Hazard ratio
95% confidence
interval P value
Age (year) 1.066 1.040–1.093 <.001
Sex (male/female) 2.077 1.020–4.230 .044
FEV1 (%), 79.6/>79.6 1.193 0.586–2.428 .627
Treatment, nonsurgical/surgical 1.992 1.021–3.884 .043
Type of aspergilloma
(complex/simple)
2.349 0.775–7.125 .131
Age was analyzed as a continuous variable. FEV1, Forced expiratory volume for 1
second.ardiovascular Surgery c Volume 138, Number 4 823
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showed 3.3% operative mortality and 33.3% morbidity
with the majority of deaths and complications occurring in
patients with complex aspergilloma. Park and associates7 re-
ported 0.9% operative mortality and 23.6%morbidity when
treating 110 patients with aspergilloma. Even though post-
operative morbidity was up to 23.6% in recent series, trou-
blesome complications were in the acceptable range, and the
majority was managed without difficulty. In our series, we
experienced 4.4% mortality and 29.6% morbidity with
135 patients.
In a comparison study between medical and surgical ther-
apy, Jewkes and coworkers3 found a similar 5-year survival
between the medical (65%) and surgical (75%) options in
patients with minor or no hemoptysis. However, for patients
with recurrent hemoptysis or a single major bleeding, the
5-year survival was 41% for medical and 84% for surgical
groups, suggesting the necessity for surgical therapy for this
group of patients. In our series, the overall 10-year survival
of group A (84.8%) was significantly better than the sur-
vival of group B (56.7%). In multivariate analysis, surgical
treatment was a significantly favorable prognostic factor.
This result implies that surgical treatment offers the possibil-
ity of a survival benefit in patients with pulmonary aspergil-
loma. For patients without symptoms, surgical resection has
not been considered. In our series, the presence of symptoms
was not a significant prognostic factor in patients with asper-
gilloma. For patients without symptoms, the overall 10-year
survival rates of patients with surgical procedure (n ¼ 31)
was better than that of patients with nonsurgical treatment
(n ¼ 41; 82.5% vs 50.5%, P ¼ .011). When we select the
treatment modality for patients, we should consider the
risk and the benefit of the treatment. Recent advances in tho-
racic surgery have decreased the risk of surgery, as we have
noted; the mortality rate of reports after the early 2000s were
from 0% to 4% compared with up to 43% of previous se-
ries, meaning that the axis of balance for the decision could
be moved toward the surgical treatment because the weigh
of the risk is decreased. When we consider the risk of he-
moptysis-related mortality from aspergilloma and the benefit
of permanent cure from surgical treatment, surgical resection
could be considered for patients who have no symptoms and
a tolerable pulmonary reserve with acceptable risk (4.4%
mortality in all patients, 0% mortality in simple aspergil-
loma). The results from our series are consistent with recent
trends regarding surgical management of both symptomatic
and asymptomatic aspergilloma with respect to mortality
and morbidity. We thought this study could be helpful to
select treatment modality for pulmonary aspergilloma in
a recent advanced era.
Our study has some limitations. First, those patients for
surgical treatment were selected among the patients with as-
pergilloma, and the nature of this study was retrospectively
designed.We attempted to overcome this limitation by using824 The Journal of Thoracic and Cardiovascular Sua multivariate analysis and propensity score-matched sub-
group analysis. Using multivariate analysis, we found that
surgical treatment was a favorable factor. In a subgroup anal-
ysis with the propensity score-matched group, the patients
with surgical treatment had better overall 10-year survival
rates. We thought that a better comparison would be
achieved by multivariate analysis in propensity score-
matched subgroups, but our number of patients after match-
ing was relatively too small to achieve significance (data was
not shown). Only multicenter data collection could yield sig-
nificance because our number of patients was relatively large
and there were no comparison reports with large number of
patients in the recent era. Second, treatment options were not
homogenous during the study period. Surgical options were
decided upon by surgeons and physicians without standard
consensus because of the retrospective nature of this study
and the lack of a worldwide standard consensus for the treat-
ment of pulmonary aspergilloma. Further discussion with
a larger population is necessary.
In summary, our results indicate that (1) early morbidity
and mortality rates of surgical treatment for pulmonary as-
pergilloma are acceptable, (2) surgical treatment is helpful
not only to reduce symptoms but also to prolong the survival
of patients with pulmonary aspergilloma. Although more
studies are needed, our data support the conclusion that sur-
gical resection should be considered for patients with both
symptomatic and asymptomatic pulmonary aspergilloma
who have an acceptable pulmonary reserve.
All the work was performed at the Yonsei University Col-
lege of Medicine, Seoul, South Korea. The authors do not
have actual or potential conflict of interest.
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